ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...

GuruFocus.com10-10

Total Revenue: $24.5 million for fiscal year 2024, a 19% increase over the previous year. Fourth Quarter Revenue: $6.5 million, marking another quarter of record revenue growth. Gross Profit Margin: ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2474205358?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NNWV_HBVc2G2ePTI82j1eg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5a673207e05f933ce533b56c6dedf625","is_english":true,"pubTime":"2024-10-10 03:21","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2474205358","market":"us","top_or_hot":-1,"title":"ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...","media":"GuruFocus.com","content":"<div>\n<p>Total Revenue: $24.5 million for fiscal year 2024, a 19% increase over the previous year.\nFourth Quarter Revenue: $6.5 million, marking another quarter of record revenue growth.\nGross Profit Margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunoprecise-antibodies-ltd-ipa-q4-192111794.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunoPrecise Antibodies Ltd (IPA) Q4 2024 Earnings Call Highlights: Record Revenue Growth Amid ...\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-10 03:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/immunoprecise-antibodies-ltd-ipa-q4-192111794.html><strong>GuruFocus.com</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Total Revenue: $24.5 million for fiscal year 2024, a 19% increase over the previous year.\nFourth Quarter Revenue: $6.5 million, marking another quarter of record revenue growth.\nGross Profit Margin: ...</p>\n\n<a href=\"https://finance.yahoo.com/news/immunoprecise-antibodies-ltd-ipa-q4-192111794.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPA","symbol_name":"Immunoprecise Antibodies Ltd","start_time":0,"source_url":"https://finance.yahoo.com/news/immunoprecise-antibodies-ltd-ipa-q4-192111794.html","article_id":"2474205358","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NNWV_HBVc2G2ePTI82j1eg--~B/aD01MDA7dz01MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/5a673207e05f933ce533b56c6dedf625"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2474205358","pubTimestamp":1728501671,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Total Revenue: $24.5 million for fiscal year 2024, a 19% increase over the previous year.Fourth Quarter Revenue: $6.5 million, marking another quarter of record revenue growth.Gross Profit Margin: 49%, down from 56% in the previous year.Operating Expenses: Decreased by 30% to $26 million, excluding asset impairment.R&D Expenses: Reduced to $4 million from $14.1 million in the previous year.Net Loss: $27.2 million for fiscal year 2024, compared to $26.6 million in the prior year.Cash Burn: Significant reduction in cash burn year-over-year.Unrestricted Cash: $3.5 million at the end of fiscal 2024.Use of Cash: $4.8 million in fiscal 2024, compared to $22.4 million in fiscal 2023.Convertible Debentures: Agreement to sell and issue $3 million with an 8% annual interest rate.GuruFocus has detected 6 Warning Signs with IPA.ImmunoPrecise Antibodies Ltd  reported a 19% increase in total revenue for fiscal year 2024, reaching $24.5 million, which is above the industry average.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"IPA":"Immunoprecise Antibodies Ltd"},"translate_title":"ImmunoPrecise Antibodies Ltd(IPA)2024年第四季度收益看涨期权亮点：创纪录的收入增长...","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPA":1},"content_text":"Total Revenue: $24.5 million for fiscal year 2024, a 19% increase over the previous year.\nFourth Quarter Revenue: $6.5 million, marking another quarter of record revenue growth.\nGross Profit Margin: 49%, down from 56% in the previous year.\nOperating Expenses: Decreased by 30% to $26 million, excluding asset impairment.\nR&D Expenses: Reduced to $4 million from $14.1 million in the previous year.\nNet Loss: $27.2 million for fiscal year 2024, compared to $26.6 million in the prior year.\nCash Burn: Significant reduction in cash burn year-over-year.\nUnrestricted Cash: $3.5 million at the end of fiscal 2024.\nUse of Cash: $4.8 million in fiscal 2024, compared to $22.4 million in fiscal 2023.\nConvertible Debentures: Agreement to sell and issue $3 million with an 8% annual interest rate.\n\n\nWarning! GuruFocus has detected 6 Warning Signs with IPA.\n\nRelease Date: July 29, 2024\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n Positive Points \n\nImmunoPrecise Antibodies Ltd (NASDAQ:IPA) reported a 19% increase in total revenue for fiscal year 2024, reaching $24.5 million, which is above the industry average.\nThe company achieved its fifth consecutive quarter of record revenue, driven by the success of its end-to-end services and the commercial launch of LENSai.\nSignificant reduction in cash burn year-over-year, reflecting effective cash flow management and strategic investments in growth.\nThe launch of LENSai API and vector search software has been well-received, with increasing interest from pharmaceutical, healthcare, and technology companies.\nImmunoPrecise Antibodies Ltd (NASDAQ:IPA) has entered into strategic collaborations, such as with PGxAI, to advance personalized medicine and improve patient outcomes.\n\n Negative Points \n\nDespite strong revenue growth, the company's stock valuation does not reflect its intrinsic value, indicating a disconnect between market cap and achievements.\nGross profit margin decreased from 56% to 49% due to additional costs associated with wet lab expansion and inflationary pressures.\nThe commercialization of BioStrand's LENSai technology has been more challenging than anticipated, leading to a significant write-down.\nThe company reported a net loss of $27.2 million for fiscal year 2024, including noncash impairment losses on goodwill and intangible assets.\nImmunoPrecise Antibodies Ltd (NASDAQ:IPA) faces funding needs and has been conducting small equity raises to support its operations and growth initiatives.\n\n Q & A Highlights \nQ: Can you provide an update on the milestones and their impact on financials, particularly regarding the structured AI lab deal with licensee? A: Jennifer Bath, CEO: The early access rollout has begun to generate initial revenues, particularly with one partner using the LENSai API. This is a phased approach, and we expect more significant revenues as the program progresses. The marketing push for LENSai API has ramped up, and we anticipate subscription model revenues to start rolling in around Q2 of fiscal 2025.\nQ: What challenges did you face with the BioStrand acquisition, and how do you plan to earn a return on that investment? A: Jennifer Bath, CEO: The integration of BioStrand into the antibody discovery space took longer than expected. We faced challenges in balancing investments between data management and the LENSai BioIntelligence suite. However, we now have over 80 applications built for drug discovery, validated in the lab, and are seeing increasing traction and revenue from BioStrand.\nQ: How have conversations with potential partners changed since completing end-to-end programs using LENSai? A: Jennifer Bath, CEO: The successful use of LENSai in silico programs has positively impacted conversations with partners, proving the technology's legitimacy. This has transformed our ability to provide evidence and demonstrate capabilities, leading to more rapid buy-in, especially from technology companies.\nQ: Regarding revenue growth guidance for fiscal 2025, what are the expectations, and how sustainable is the growth from expanded facilities in the Netherlands? A: Jennifer Bath, CEO: We expect sustainable growth driven by expanded capabilities in the Netherlands, particularly in antibody development and B-Cell technology. Our market intelligence indicates low-double-digit growth, but we are outperforming peers due to vendor consolidation and our reputation for excellence.\nQ: Given the challenging market conditions and funding needs, are there considerations for strategic alternatives to realize value? A: Jennifer Bath, CEO: While open to maximizing shareholder value, we believe our current valuation does not reflect our opportunities. We are not interested in giving away the upside from our investments and remain focused on executing our strategy to unlock the true value of IPA.\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.This article first appeared on \nGuruFocus.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2474205358"}